Q2 2026 saw improved profitability, strong cash reserves, and pipeline progress, with revenue rising to $163.6M and operating loss narrowing to $7M. Diagnostics and pharma segments both improved, while guidance for 2026 was raised on the back of robust product and partnership revenue.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.